User login
FDA OKs first orally disintegrating agent for rapid migraine relief
In clinical testing, a single 75-mg dose of rimegepant provided rapid migraine pain relief with patients returning to normal activities within 1 hour, with sustained benefit lasting up to 2 days in many patients. The majority of patients (86%) treated with a single dose did not need a migraine rescue medication within 24 hours.
“I see many patients in my practice whose lives are disrupted by migraine, afraid to go about everyday life in case of a migraine attack,” Peter Goadsby, MD, PhD, professor of neurology and director of the King’s Clinical Research Facility, King’s College Hospital, London, UK, said in a news release from Biohaven.
“Many feel unsure if their acute treatment will work and if they can manage the side effects. With the FDA approval of Nurtec ODT, there is renewed hope for people living with migraine that they can get back to living their lives without fear of the next attack,” said Goadsby.
More than 3100 patients have been treated with rimegepant with more than 113,000 doses administered in clinical trials, including a 1-year long-term safety study, the company said.
In the phase 3 trial, rimegepant achieved statistical significance on the co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) 2 hours after administration compared with placebo.
Rimegepant also showed statistical superiority at 1 hour for pain relief (reduction of moderate or severe pain to no pain or mild pain) and return to normal function.
In many patients, the benefits of pain freedom, pain relief, return to normal function, and freedom from MBS with a single dose lasted up to 48 hours.
Rimegepant was generally well tolerated. The most common adverse reaction was nausea (2%) in patients who received rimegepant compared with 0.4% of patients who received placebo.
“Everyone knows someone living with migraine, yet it remains an invisible disease that is often overlooked and misunderstood,” Mary Franklin, executive director of the National Headache Foundation, commented in the news release.
“The approval of Nurtec ODT is exciting for people with migraine as it provides a new treatment option to help people regain control of their attacks and their lives,” said Franklin.
Nurtec ODT will be available in pharmacies in early March in packs of eight tablets. Each eight-tablet pack covers treatment of eight migraine attacks with one dose, as needed, up to once daily. Sample packs containing two tablets will also be made available to healthcare providers.
Rimegepant is not indicated for the preventive treatment of migraine. The company expects to report top-line results from its prevention of migraine trial later this quarter.
This story first appeared on Medscape.com.
In clinical testing, a single 75-mg dose of rimegepant provided rapid migraine pain relief with patients returning to normal activities within 1 hour, with sustained benefit lasting up to 2 days in many patients. The majority of patients (86%) treated with a single dose did not need a migraine rescue medication within 24 hours.
“I see many patients in my practice whose lives are disrupted by migraine, afraid to go about everyday life in case of a migraine attack,” Peter Goadsby, MD, PhD, professor of neurology and director of the King’s Clinical Research Facility, King’s College Hospital, London, UK, said in a news release from Biohaven.
“Many feel unsure if their acute treatment will work and if they can manage the side effects. With the FDA approval of Nurtec ODT, there is renewed hope for people living with migraine that they can get back to living their lives without fear of the next attack,” said Goadsby.
More than 3100 patients have been treated with rimegepant with more than 113,000 doses administered in clinical trials, including a 1-year long-term safety study, the company said.
In the phase 3 trial, rimegepant achieved statistical significance on the co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) 2 hours after administration compared with placebo.
Rimegepant also showed statistical superiority at 1 hour for pain relief (reduction of moderate or severe pain to no pain or mild pain) and return to normal function.
In many patients, the benefits of pain freedom, pain relief, return to normal function, and freedom from MBS with a single dose lasted up to 48 hours.
Rimegepant was generally well tolerated. The most common adverse reaction was nausea (2%) in patients who received rimegepant compared with 0.4% of patients who received placebo.
“Everyone knows someone living with migraine, yet it remains an invisible disease that is often overlooked and misunderstood,” Mary Franklin, executive director of the National Headache Foundation, commented in the news release.
“The approval of Nurtec ODT is exciting for people with migraine as it provides a new treatment option to help people regain control of their attacks and their lives,” said Franklin.
Nurtec ODT will be available in pharmacies in early March in packs of eight tablets. Each eight-tablet pack covers treatment of eight migraine attacks with one dose, as needed, up to once daily. Sample packs containing two tablets will also be made available to healthcare providers.
Rimegepant is not indicated for the preventive treatment of migraine. The company expects to report top-line results from its prevention of migraine trial later this quarter.
This story first appeared on Medscape.com.
In clinical testing, a single 75-mg dose of rimegepant provided rapid migraine pain relief with patients returning to normal activities within 1 hour, with sustained benefit lasting up to 2 days in many patients. The majority of patients (86%) treated with a single dose did not need a migraine rescue medication within 24 hours.
“I see many patients in my practice whose lives are disrupted by migraine, afraid to go about everyday life in case of a migraine attack,” Peter Goadsby, MD, PhD, professor of neurology and director of the King’s Clinical Research Facility, King’s College Hospital, London, UK, said in a news release from Biohaven.
“Many feel unsure if their acute treatment will work and if they can manage the side effects. With the FDA approval of Nurtec ODT, there is renewed hope for people living with migraine that they can get back to living their lives without fear of the next attack,” said Goadsby.
More than 3100 patients have been treated with rimegepant with more than 113,000 doses administered in clinical trials, including a 1-year long-term safety study, the company said.
In the phase 3 trial, rimegepant achieved statistical significance on the co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) 2 hours after administration compared with placebo.
Rimegepant also showed statistical superiority at 1 hour for pain relief (reduction of moderate or severe pain to no pain or mild pain) and return to normal function.
In many patients, the benefits of pain freedom, pain relief, return to normal function, and freedom from MBS with a single dose lasted up to 48 hours.
Rimegepant was generally well tolerated. The most common adverse reaction was nausea (2%) in patients who received rimegepant compared with 0.4% of patients who received placebo.
“Everyone knows someone living with migraine, yet it remains an invisible disease that is often overlooked and misunderstood,” Mary Franklin, executive director of the National Headache Foundation, commented in the news release.
“The approval of Nurtec ODT is exciting for people with migraine as it provides a new treatment option to help people regain control of their attacks and their lives,” said Franklin.
Nurtec ODT will be available in pharmacies in early March in packs of eight tablets. Each eight-tablet pack covers treatment of eight migraine attacks with one dose, as needed, up to once daily. Sample packs containing two tablets will also be made available to healthcare providers.
Rimegepant is not indicated for the preventive treatment of migraine. The company expects to report top-line results from its prevention of migraine trial later this quarter.
This story first appeared on Medscape.com.
FDA approves first IV migraine prevention drug
As previously reported by Medscape Medical News, the drug’s approval is based on results from two clinical studies – PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine.
The recommended dose is 100 mg every 3 months although some patients may benefit from a dose of 300 mg, the company notes. Lundbeck reports that the drug will likely be available in early April.
Roger Cady, MD, vice-president of neurology at Lundbeck, told Medscape Medical News the drug has almost immediate efficacy.
“Because it’s an IV [medication], it has very rapid benefit. In fact, we were able to demonstrate benefit on Day 1. Truly, it is going to impact on the unmet need for patients because of its profile, the way it’s delivered, and its uniqueness,” Cady said.
“Having preventive activity the day following an infusion is really important. We have in our data, if you take that time between the first day and the 28th day, whether they have episodic migraine or chronic migraine, that about 30% of the population had a 75% or more reduction in migraine days through that first month,” he added.
The clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of Vyepti as early as day 1 post-infusion, and the percentage of patients experiencing a migraine was lower for Vyepti than with placebo for most of the first 7 days, the company reports.
The safety of Vyepti was evaluated in 2076 patients with migraine who received at least one dose of the drug. The most common adverse reactions were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with Vyepti discontinued treatment as a result of adverse reactions.
“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine improvement through 6 months, which is clinically meaningful to both physicians and patients,” said Peter Goadsby, MD, professor of neurology at King’s College, London, UK, and the University of California, San Francisco, in a press release. “Vyepti is a valuable addition for the treatment of migraine, which can help reduce the burden of this serious disease.”
This article first appeared on Medscape.com.
As previously reported by Medscape Medical News, the drug’s approval is based on results from two clinical studies – PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine.
The recommended dose is 100 mg every 3 months although some patients may benefit from a dose of 300 mg, the company notes. Lundbeck reports that the drug will likely be available in early April.
Roger Cady, MD, vice-president of neurology at Lundbeck, told Medscape Medical News the drug has almost immediate efficacy.
“Because it’s an IV [medication], it has very rapid benefit. In fact, we were able to demonstrate benefit on Day 1. Truly, it is going to impact on the unmet need for patients because of its profile, the way it’s delivered, and its uniqueness,” Cady said.
“Having preventive activity the day following an infusion is really important. We have in our data, if you take that time between the first day and the 28th day, whether they have episodic migraine or chronic migraine, that about 30% of the population had a 75% or more reduction in migraine days through that first month,” he added.
The clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of Vyepti as early as day 1 post-infusion, and the percentage of patients experiencing a migraine was lower for Vyepti than with placebo for most of the first 7 days, the company reports.
The safety of Vyepti was evaluated in 2076 patients with migraine who received at least one dose of the drug. The most common adverse reactions were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with Vyepti discontinued treatment as a result of adverse reactions.
“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine improvement through 6 months, which is clinically meaningful to both physicians and patients,” said Peter Goadsby, MD, professor of neurology at King’s College, London, UK, and the University of California, San Francisco, in a press release. “Vyepti is a valuable addition for the treatment of migraine, which can help reduce the burden of this serious disease.”
This article first appeared on Medscape.com.
As previously reported by Medscape Medical News, the drug’s approval is based on results from two clinical studies – PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine.
The recommended dose is 100 mg every 3 months although some patients may benefit from a dose of 300 mg, the company notes. Lundbeck reports that the drug will likely be available in early April.
Roger Cady, MD, vice-president of neurology at Lundbeck, told Medscape Medical News the drug has almost immediate efficacy.
“Because it’s an IV [medication], it has very rapid benefit. In fact, we were able to demonstrate benefit on Day 1. Truly, it is going to impact on the unmet need for patients because of its profile, the way it’s delivered, and its uniqueness,” Cady said.
“Having preventive activity the day following an infusion is really important. We have in our data, if you take that time between the first day and the 28th day, whether they have episodic migraine or chronic migraine, that about 30% of the population had a 75% or more reduction in migraine days through that first month,” he added.
The clinical trial program demonstrated a treatment benefit over placebo that was observed for both doses of Vyepti as early as day 1 post-infusion, and the percentage of patients experiencing a migraine was lower for Vyepti than with placebo for most of the first 7 days, the company reports.
The safety of Vyepti was evaluated in 2076 patients with migraine who received at least one dose of the drug. The most common adverse reactions were nasopharyngitis and hypersensitivity. In PROMISE-1 and PROMISE-2, 1.9% of patients treated with Vyepti discontinued treatment as a result of adverse reactions.
“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine improvement through 6 months, which is clinically meaningful to both physicians and patients,” said Peter Goadsby, MD, professor of neurology at King’s College, London, UK, and the University of California, San Francisco, in a press release. “Vyepti is a valuable addition for the treatment of migraine, which can help reduce the burden of this serious disease.”
This article first appeared on Medscape.com.
FROM MEDSCAPE.COM
Episodic Migraines Not Linked to Subsequent Sleep Disturbances
Key clinical point: Occurrence of headache is not associated with subsequent sleep period characterized by shorter sleep duration, higher sleep disruption, or poorer sleep quality in adults with episodic migraine.
Major finding: The average nightly objective sleep duration, efficiency, and wake after sleep onset (WASO) were 7.3±1.2 hours, 89.5%±3.3%, and 44.8±17.0 minutes, respectively. Objective sleep duration was 7.3 (95% confidence interval, 1.5-13.0) minutes longer on nights after a headache day vs. nights on headache-free days. Actigraphically assessed sleep efficiency and WASO did not differ on nights after headache days vs. headache-free days.
Study details: A prospective cohort study of 98 adults (mean age, 35 years, with an average of five migraine headaches/month) with episodic migraine who provided 4,406 days of data; actigraphic sleep data were assessed for six weeks.
Disclosures: This study was funded by grants from the National Institute of Neurological Disorders and Stroke and the American Sleep Medicine Foundation and received financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Bertisch reported receiving research support from Merck, Sharpe & Dohme, ApniMed and Lockheed Martin and served as a consultant for Verily.
Citation: Vgontzas A et al. Sleep. 2020 Jan 13. doi: 10.1093/sleep/zsaa001.
Key clinical point: Occurrence of headache is not associated with subsequent sleep period characterized by shorter sleep duration, higher sleep disruption, or poorer sleep quality in adults with episodic migraine.
Major finding: The average nightly objective sleep duration, efficiency, and wake after sleep onset (WASO) were 7.3±1.2 hours, 89.5%±3.3%, and 44.8±17.0 minutes, respectively. Objective sleep duration was 7.3 (95% confidence interval, 1.5-13.0) minutes longer on nights after a headache day vs. nights on headache-free days. Actigraphically assessed sleep efficiency and WASO did not differ on nights after headache days vs. headache-free days.
Study details: A prospective cohort study of 98 adults (mean age, 35 years, with an average of five migraine headaches/month) with episodic migraine who provided 4,406 days of data; actigraphic sleep data were assessed for six weeks.
Disclosures: This study was funded by grants from the National Institute of Neurological Disorders and Stroke and the American Sleep Medicine Foundation and received financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Bertisch reported receiving research support from Merck, Sharpe & Dohme, ApniMed and Lockheed Martin and served as a consultant for Verily.
Citation: Vgontzas A et al. Sleep. 2020 Jan 13. doi: 10.1093/sleep/zsaa001.
Key clinical point: Occurrence of headache is not associated with subsequent sleep period characterized by shorter sleep duration, higher sleep disruption, or poorer sleep quality in adults with episodic migraine.
Major finding: The average nightly objective sleep duration, efficiency, and wake after sleep onset (WASO) were 7.3±1.2 hours, 89.5%±3.3%, and 44.8±17.0 minutes, respectively. Objective sleep duration was 7.3 (95% confidence interval, 1.5-13.0) minutes longer on nights after a headache day vs. nights on headache-free days. Actigraphically assessed sleep efficiency and WASO did not differ on nights after headache days vs. headache-free days.
Study details: A prospective cohort study of 98 adults (mean age, 35 years, with an average of five migraine headaches/month) with episodic migraine who provided 4,406 days of data; actigraphic sleep data were assessed for six weeks.
Disclosures: This study was funded by grants from the National Institute of Neurological Disorders and Stroke and the American Sleep Medicine Foundation and received financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Bertisch reported receiving research support from Merck, Sharpe & Dohme, ApniMed and Lockheed Martin and served as a consultant for Verily.
Citation: Vgontzas A et al. Sleep. 2020 Jan 13. doi: 10.1093/sleep/zsaa001.
Migraine: What Are the Risk Factors for Flunarizine-Induced Parkinsonism?
Key clinical point: In patients with migraine, flunarizine (Fz)-induced parkinsonism (FIP) is associated with older age, history of comorbidities, exposure to high dose of Fz, and longer duration of exposure to Fz.
Major finding: In patients aged 45-64 years and 65 years or older, FIP risk was 3.18 and 4.89 times, respectively, higher in the Fz-treated group than in the controls. Compared with control group, the risk for FIP in those with comorbidities, annual cumulative Fz dose ≥445 mg, and Fz use for ≥60 days was 4.54-, 7.69-, and 8.49-fold, respectively, higher than in the control group.
Study details: A population-based study used data from Taiwan’s National Health Insurance Research Database and included 6,470 patients with migraine who were divided into two groups, based on their exposure (n=3,235) or non-exposure to Fz (n=3,235).
Disclosures: This study was supported by grants from the Taiwan Ministry of Health and Welfare Clinical Trial Center; China Medical University Hospital; Academia Sinica Stroke Biosignature Project; MOST Clinical Trial Consortium for Stroke; Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The authors declared no conflict of interest.
Citation: Lin W et al. Front Pharmacol. 2019 Dec 19. doi: 10.3389/fphar.2019.01495.
Key clinical point: In patients with migraine, flunarizine (Fz)-induced parkinsonism (FIP) is associated with older age, history of comorbidities, exposure to high dose of Fz, and longer duration of exposure to Fz.
Major finding: In patients aged 45-64 years and 65 years or older, FIP risk was 3.18 and 4.89 times, respectively, higher in the Fz-treated group than in the controls. Compared with control group, the risk for FIP in those with comorbidities, annual cumulative Fz dose ≥445 mg, and Fz use for ≥60 days was 4.54-, 7.69-, and 8.49-fold, respectively, higher than in the control group.
Study details: A population-based study used data from Taiwan’s National Health Insurance Research Database and included 6,470 patients with migraine who were divided into two groups, based on their exposure (n=3,235) or non-exposure to Fz (n=3,235).
Disclosures: This study was supported by grants from the Taiwan Ministry of Health and Welfare Clinical Trial Center; China Medical University Hospital; Academia Sinica Stroke Biosignature Project; MOST Clinical Trial Consortium for Stroke; Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The authors declared no conflict of interest.
Citation: Lin W et al. Front Pharmacol. 2019 Dec 19. doi: 10.3389/fphar.2019.01495.
Key clinical point: In patients with migraine, flunarizine (Fz)-induced parkinsonism (FIP) is associated with older age, history of comorbidities, exposure to high dose of Fz, and longer duration of exposure to Fz.
Major finding: In patients aged 45-64 years and 65 years or older, FIP risk was 3.18 and 4.89 times, respectively, higher in the Fz-treated group than in the controls. Compared with control group, the risk for FIP in those with comorbidities, annual cumulative Fz dose ≥445 mg, and Fz use for ≥60 days was 4.54-, 7.69-, and 8.49-fold, respectively, higher than in the control group.
Study details: A population-based study used data from Taiwan’s National Health Insurance Research Database and included 6,470 patients with migraine who were divided into two groups, based on their exposure (n=3,235) or non-exposure to Fz (n=3,235).
Disclosures: This study was supported by grants from the Taiwan Ministry of Health and Welfare Clinical Trial Center; China Medical University Hospital; Academia Sinica Stroke Biosignature Project; MOST Clinical Trial Consortium for Stroke; Tseng-Lien Lin Foundation, Taichung, Taiwan; and Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The authors declared no conflict of interest.
Citation: Lin W et al. Front Pharmacol. 2019 Dec 19. doi: 10.3389/fphar.2019.01495.
Migraine: Vitamin D Might Improve Headache Characteristics and Reduce Inflammation
Key clinical point: Vitamin D3 supplementation might improve headache characteristics and protect against inflammation in migraine.
Major finding: Analysis of covariance adjusted for baseline values and confounders showed that vitamin D3 supplemented group had significantly lower headache days, attacks frequency, duration and severity, and reduced analgesics consumption compared with the placebo group
(P less than 0.05). Patients receiving vitamin D3 had a significant reduction in inducible nitric oxide synthase
(P=0.001) and serum levels of interleukin-6 (P=0.055) compared with placebo.
Study details: Study of 80 patients with episodic migraine randomly assigned to a daily dose of vitamin D3 2,000 IU (50 μg) or placebo for 12 weeks.
Disclosures: The study was supported by Tehran University of Medical Sciences & health Services grant. The authors declared no conflict of interest.
Citation: Ghorbani Z et al. Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04220-8.
Key clinical point: Vitamin D3 supplementation might improve headache characteristics and protect against inflammation in migraine.
Major finding: Analysis of covariance adjusted for baseline values and confounders showed that vitamin D3 supplemented group had significantly lower headache days, attacks frequency, duration and severity, and reduced analgesics consumption compared with the placebo group
(P less than 0.05). Patients receiving vitamin D3 had a significant reduction in inducible nitric oxide synthase
(P=0.001) and serum levels of interleukin-6 (P=0.055) compared with placebo.
Study details: Study of 80 patients with episodic migraine randomly assigned to a daily dose of vitamin D3 2,000 IU (50 μg) or placebo for 12 weeks.
Disclosures: The study was supported by Tehran University of Medical Sciences & health Services grant. The authors declared no conflict of interest.
Citation: Ghorbani Z et al. Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04220-8.
Key clinical point: Vitamin D3 supplementation might improve headache characteristics and protect against inflammation in migraine.
Major finding: Analysis of covariance adjusted for baseline values and confounders showed that vitamin D3 supplemented group had significantly lower headache days, attacks frequency, duration and severity, and reduced analgesics consumption compared with the placebo group
(P less than 0.05). Patients receiving vitamin D3 had a significant reduction in inducible nitric oxide synthase
(P=0.001) and serum levels of interleukin-6 (P=0.055) compared with placebo.
Study details: Study of 80 patients with episodic migraine randomly assigned to a daily dose of vitamin D3 2,000 IU (50 μg) or placebo for 12 weeks.
Disclosures: The study was supported by Tehran University of Medical Sciences & health Services grant. The authors declared no conflict of interest.
Citation: Ghorbani Z et al. Neurol Sci. 2020 Jan 2. doi: 10.1007/s10072-019-04220-8.
Low Sleep Efficiency Linked to Higher Risk of Migraine
Key clinical point: Sleep fragmentation (defined by low sleep efficiency) is associated with a higher risk of migraine onset on day 1; short sleep duration and low sleep quality are not temporally associated with migraine.
Major finding: Low sleep efficiency was associated with 39% higher odds of headache on day 1. Sleep duration ≤6.5 hours and poor sleep quality were not associated with migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
Study details: The data were obtained from a prospective study of 98 adults with episodic migraine.
Disclosures: This study was funded by grants from the National Institute of Neurologic Disorders and Stroke and the American Sleep Medicine Foundation; received financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Bertisch reported receiving research support from Merck, Sharpe & Dohme and Lockheed Martin and served as a consultant for Verily.
Citation: Bertisch SM et al. Neurology. 2019 Dec 16. doi: 10.1212/WNL.0000000000008740.
Key clinical point: Sleep fragmentation (defined by low sleep efficiency) is associated with a higher risk of migraine onset on day 1; short sleep duration and low sleep quality are not temporally associated with migraine.
Major finding: Low sleep efficiency was associated with 39% higher odds of headache on day 1. Sleep duration ≤6.5 hours and poor sleep quality were not associated with migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
Study details: The data were obtained from a prospective study of 98 adults with episodic migraine.
Disclosures: This study was funded by grants from the National Institute of Neurologic Disorders and Stroke and the American Sleep Medicine Foundation; received financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Bertisch reported receiving research support from Merck, Sharpe & Dohme and Lockheed Martin and served as a consultant for Verily.
Citation: Bertisch SM et al. Neurology. 2019 Dec 16. doi: 10.1212/WNL.0000000000008740.
Key clinical point: Sleep fragmentation (defined by low sleep efficiency) is associated with a higher risk of migraine onset on day 1; short sleep duration and low sleep quality are not temporally associated with migraine.
Major finding: Low sleep efficiency was associated with 39% higher odds of headache on day 1. Sleep duration ≤6.5 hours and poor sleep quality were not associated with migraine onset on the day immediately following the sleep period (day 0) and the following day (day 1).
Study details: The data were obtained from a prospective study of 98 adults with episodic migraine.
Disclosures: This study was funded by grants from the National Institute of Neurologic Disorders and Stroke and the American Sleep Medicine Foundation; received financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Bertisch reported receiving research support from Merck, Sharpe & Dohme and Lockheed Martin and served as a consultant for Verily.
Citation: Bertisch SM et al. Neurology. 2019 Dec 16. doi: 10.1212/WNL.0000000000008740.
Migraine Linked to Adverse Pregnancy Outcomes
Key clinical point: Pregnant women with a history of migraine are at an increased risk of adverse outcomes, including preeclampsia (PE) and low birth weight (LBW).
Major finding: Women with migraine had a higher risk for PE (odds ratio, 2.07; 95% confidence interval, 1.51-2.85) and LBW (odds ratio, 1.18; 95% confidence interval, 1.03-1.34) compared with women without migraine. No significant association was observed between the history of migraine and preterm birth or small for gestational age.
Study details: A systematic review and meta-analysis of 14 studies.
Disclosures: Authors declared no conflict of interest.
Citation: Aukes AM et al. Obstet Gynecol Surv. 2019 Dec. doi: 10.1097/OGX.0000000000000738.
Key clinical point: Pregnant women with a history of migraine are at an increased risk of adverse outcomes, including preeclampsia (PE) and low birth weight (LBW).
Major finding: Women with migraine had a higher risk for PE (odds ratio, 2.07; 95% confidence interval, 1.51-2.85) and LBW (odds ratio, 1.18; 95% confidence interval, 1.03-1.34) compared with women without migraine. No significant association was observed between the history of migraine and preterm birth or small for gestational age.
Study details: A systematic review and meta-analysis of 14 studies.
Disclosures: Authors declared no conflict of interest.
Citation: Aukes AM et al. Obstet Gynecol Surv. 2019 Dec. doi: 10.1097/OGX.0000000000000738.
Key clinical point: Pregnant women with a history of migraine are at an increased risk of adverse outcomes, including preeclampsia (PE) and low birth weight (LBW).
Major finding: Women with migraine had a higher risk for PE (odds ratio, 2.07; 95% confidence interval, 1.51-2.85) and LBW (odds ratio, 1.18; 95% confidence interval, 1.03-1.34) compared with women without migraine. No significant association was observed between the history of migraine and preterm birth or small for gestational age.
Study details: A systematic review and meta-analysis of 14 studies.
Disclosures: Authors declared no conflict of interest.
Citation: Aukes AM et al. Obstet Gynecol Surv. 2019 Dec. doi: 10.1097/OGX.0000000000000738.
Migraineurs Likely to Exhibit Metacognitive Deficits
Key clinical point: Patients with migraine are likely to have metacognitive deficits.
Major finding: Patients with migraine performed worse on measures of metacognitive functions, including accuracy score (P = .012), global monitoring (P = .015), monetary gains (P = .022), and control sensitivity (P = .027) compared with control participants.
Study details: An Italian study evaluated the metacognitive abilities of 64 patients with chronic and episodic migraine and 29 healthy control participants.
Disclosures: The authors declared no conflicts of interest.
Citation: Zucca M et al. J Clin Neurosci. 2020 Jan 5. doi: 10.1016/j.jocn.2019.12.048.
Key clinical point: Patients with migraine are likely to have metacognitive deficits.
Major finding: Patients with migraine performed worse on measures of metacognitive functions, including accuracy score (P = .012), global monitoring (P = .015), monetary gains (P = .022), and control sensitivity (P = .027) compared with control participants.
Study details: An Italian study evaluated the metacognitive abilities of 64 patients with chronic and episodic migraine and 29 healthy control participants.
Disclosures: The authors declared no conflicts of interest.
Citation: Zucca M et al. J Clin Neurosci. 2020 Jan 5. doi: 10.1016/j.jocn.2019.12.048.
Key clinical point: Patients with migraine are likely to have metacognitive deficits.
Major finding: Patients with migraine performed worse on measures of metacognitive functions, including accuracy score (P = .012), global monitoring (P = .015), monetary gains (P = .022), and control sensitivity (P = .027) compared with control participants.
Study details: An Italian study evaluated the metacognitive abilities of 64 patients with chronic and episodic migraine and 29 healthy control participants.
Disclosures: The authors declared no conflicts of interest.
Citation: Zucca M et al. J Clin Neurosci. 2020 Jan 5. doi: 10.1016/j.jocn.2019.12.048.
TENS Can Treat Migraine Attacks in the Emergency Department
Key clinical point: Transcutaneous electrical nerve stimulation (TENS) is an effective option for treating migraine attacks in the emergency department.
Major finding: The verum group showed significant improvements on the visual analog scale change from 0 to 120 minutes (P less than .001) and a Likert-type verbal pain scale (P less than .001) compared with the sham group. The need for additional analgesics after 120 minutes was lower in the verum group vs. sham group (2.6% vs. 76.9%).
Study details: A randomized-controlled study evaluated the effectiveness of TENS for emergency treatment of migraine in the verum (n=39) and sham (n=39) groups.
Disclosures: The authors declared no conflicts of interest.
Citation: Hokenek NM et al. Am J Emerg Med. 2020 Jan 15. doi: 10.1016/j.ajem.2020.01.024.
Key clinical point: Transcutaneous electrical nerve stimulation (TENS) is an effective option for treating migraine attacks in the emergency department.
Major finding: The verum group showed significant improvements on the visual analog scale change from 0 to 120 minutes (P less than .001) and a Likert-type verbal pain scale (P less than .001) compared with the sham group. The need for additional analgesics after 120 minutes was lower in the verum group vs. sham group (2.6% vs. 76.9%).
Study details: A randomized-controlled study evaluated the effectiveness of TENS for emergency treatment of migraine in the verum (n=39) and sham (n=39) groups.
Disclosures: The authors declared no conflicts of interest.
Citation: Hokenek NM et al. Am J Emerg Med. 2020 Jan 15. doi: 10.1016/j.ajem.2020.01.024.
Key clinical point: Transcutaneous electrical nerve stimulation (TENS) is an effective option for treating migraine attacks in the emergency department.
Major finding: The verum group showed significant improvements on the visual analog scale change from 0 to 120 minutes (P less than .001) and a Likert-type verbal pain scale (P less than .001) compared with the sham group. The need for additional analgesics after 120 minutes was lower in the verum group vs. sham group (2.6% vs. 76.9%).
Study details: A randomized-controlled study evaluated the effectiveness of TENS for emergency treatment of migraine in the verum (n=39) and sham (n=39) groups.
Disclosures: The authors declared no conflicts of interest.
Citation: Hokenek NM et al. Am J Emerg Med. 2020 Jan 15. doi: 10.1016/j.ajem.2020.01.024.
Migraine is Bidirectionally Associated With Asthma
Key clinical point: Migraine and asthma have a reciprocal association with each other.
Major finding: Patients with asthma had a 47% higher risk for migraine (P less than .001) than control participants, and patients with migraine had a 37% higher risk for asthma (P less than .001).
Study details: The data were obtained from 2 Korean longitudinal follow-up studies (Study 1: 113,059 patients with asthma and 113,059 control participants; Study 2: 36,044 patients with migraine and 114,176 control participants).
Disclosures: This study was partly supported by a grant from the National Research Foundation of Korea. The authors declared no conflicts of interest.
Citation: Kim SY et al. Sci Rep. 2019 Dec 4. doi: 10.1038/s41598-019-54972-8.
Key clinical point: Migraine and asthma have a reciprocal association with each other.
Major finding: Patients with asthma had a 47% higher risk for migraine (P less than .001) than control participants, and patients with migraine had a 37% higher risk for asthma (P less than .001).
Study details: The data were obtained from 2 Korean longitudinal follow-up studies (Study 1: 113,059 patients with asthma and 113,059 control participants; Study 2: 36,044 patients with migraine and 114,176 control participants).
Disclosures: This study was partly supported by a grant from the National Research Foundation of Korea. The authors declared no conflicts of interest.
Citation: Kim SY et al. Sci Rep. 2019 Dec 4. doi: 10.1038/s41598-019-54972-8.
Key clinical point: Migraine and asthma have a reciprocal association with each other.
Major finding: Patients with asthma had a 47% higher risk for migraine (P less than .001) than control participants, and patients with migraine had a 37% higher risk for asthma (P less than .001).
Study details: The data were obtained from 2 Korean longitudinal follow-up studies (Study 1: 113,059 patients with asthma and 113,059 control participants; Study 2: 36,044 patients with migraine and 114,176 control participants).
Disclosures: This study was partly supported by a grant from the National Research Foundation of Korea. The authors declared no conflicts of interest.
Citation: Kim SY et al. Sci Rep. 2019 Dec 4. doi: 10.1038/s41598-019-54972-8.